

The sensitivity of SARS-CoV-2 antigen tests in the view of large-scale testing

Dřevínek P.¹, Hurych J.¹, Kepka Z.¹, Briksi A.¹, Kulich M.², Zajac M.¹, Hubáček P.¹

¹Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

²Department of Probability and Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic

ABSTRACT

Objectives: Antigen tests have emerged as an alternative to SARS-CoV-2 diagnostic PCR, thought to be valuable especially for the screening of bigger communities. To check appropriateness of the antigen based testing, we determined sensitivity of two point-of-care antigen tests when applied to a cohort of COVID-19 symptomatic, COVID-19 asymptomatic and healthy persons.

Methods: We examined nasopharyngeal swabs with antigen test 1 (Panbio Covid-19 Ag Rapid Test, Abbott) and antigen test 2 (Standard F Covid-19 Ag FIA, SD Biosensor). An additional nasopharyngeal and oropharyngeal swab of the same individual was checked with PCR (Allplex SARS-nCoV-2, Seegene). Within a 4-day period in October 2020, we collected specimens from 591 subjects. Of them, 290 had COVID-19 associated symptoms.

Results: While PCR positivity was detected in 223 cases, antigen test 1 and antigen test 2 were found positive in 148 (sensitivity 0.664, 95%CI 0.599, 0.722) and 141 (sensitivity 0.623, 95%CI 0.558, 0.684) patients, respectively. When only symptomatic patients were analysed, sensitivity increased to 0.738 (95%CI 0.667, 0.799) for the antigen test 1 and to 0.685 (95%CI 0.611, 0.750) for the antigen test 2. The substantial drop in sensitivity to 12.9% (95%CI 0.067, 0.234) was observed for samples with the PCR threshold cycle above > 30.

Conclusions: Low sensitivity of antigen tests leads to the considerable risk of false negativity. It is advisable to implement repeated testing with high enough frequency if the antigen test is used as a frontline screening tool, and to follow with PCR if it is applied to vulnerable populations.

KEYWORDS

SARS-CoV-2 – antigen test – sensitivity – population-wide screening – false negativity

SOUHRN

Dřevínek P., Hurych J., Kepka Z., Briksi A., Kulich M., Zajac M., Hubáček P.: Citlivost testů antigenu SARS-CoV-2 z hlediska testování ve velkém měřítku

Cíl: Test, založený na detekci antigenu SARS-CoV-2, je v souvislosti s potřebou screeningu větších skupin obyvatelstva často chápán jako alternativa k metodě PCR. Aby bylo možné posoudit vhodnost takového přístupu, hodnotili jsme senzitivitu dvou antigenních testů na skupině jedinců, zahrnujících jak pacienty s příznaky onemocnění covid-19, tak asymptomatické a zdravé osoby.

Metody: Výtěry z nosohltanu jsme vyšetřili pomocí antigenního testu č. 1 (Panbio Covid-19 Ag Rapid Test, Abbott) a antigenního testu č. 2 (Standard F Covid-19 Ag FIA, SD Biosensor). Druhý výtěr z nosohltanu, doplněný o výtěr z orofaryngu od téže osoby jsme zkontrolovali metodou PCR (Allplex SARS-nCoV-2, Seegene). Celkem jsme během 4 dní v říjnu 2020 nasbírali vzorky od 591 jedinců, z nichž 290 mělo symptomy spojené s nemocí covid-19.

Výsledky: Pozitivita metodou PCR byla zaznamenána ve 223 případech. Antigenní test č. 1 odhalil 148 pozitivních vzorků (senzitivita 0,664, 95% CI 0,599; 0,722), antigenní test č. 2 zachytil 141 pozitivit (senzitivita 0,623, 95% CI 0,558; 0,684). Senzitivita vyšetření se zvýšila u antigenního testu č. 1 na 0,738 (95 % CI 0,667; 0,799) a u antigenního testu č. 2 na 0,685 (95% CI 0,611, 0,750), pokud byli do analýzy zařazeni pouze symptomatictí jedinci. Výrazný pokles v citlivosti na 12,9 % (95% CI 0,067; 0,234) jsme pozorovali u vzorků, jejichž prahový cyklus PCR se pohyboval nad hodnotou 30.

Závěry: Nízká citlivost antigenních testů přináší významné riziko falešně negativních nálezů. Z tohoto důvodu doporučujeme v případě použití antigenního testu coby screeningového nástroje zavést testování v režimu opakování s dostatečně častou frekvencí. Testování zranitelných skupin obyvatelstva by mělo být doplňováno metodou PCR.

KLÍČOVÁ SLOVA

SARS-CoV-2 – antigenní test – senzitivita – plošné testování – falešná negativita

Epidemiol Mikrobiol Imunol, 2021; 70(3): 156–160

INTRODUCTION

Early detection of SARS-CoV-2 newly infected individuals is a key factor for making the containment measures effective. Since the beginning of the pandemic, a nucleic acid detection by PCR has become a gold standard of a novel coronavirus disease (COVID-19) diagnostics [1]. However, not fast enough turnaround time, a need for laboratory equipment and the shortage of reagents and plastic consumables raised concerns over the time about the PCR as the only front-line tool for testing, especially in surveillance regimes where great numbers of people need to be tested in relatively short time frame [2].

To overcome technical barriers associated with the use of PCR, point of care tests have been considered to complement diagnostic PCR tests and to be used for fast and onsite examination in various settings with suspected outbreaks of COVID-19. These include not only institutions and semi-closed communities such as schools and care homes (WHO interim guidance [3]), but even whole districts and countries, screened in the way of population-wide testing (ECDC Report [4]).

An attractive candidate which meets the logistic criteria for mass testing is an antigen-based detection of SARS-CoV-2 on the principle of immunochromatography. The test is inexpensive, rapid, ready and easy to use. Nevertheless, rapid antigen tests have potential limits in terms of low sensitivity that had been repeatedly documented for other respiratory viruses [5]. First reports on the performance of SARS-CoV-2 antigen detection indicated similar findings [6–8], although the manufacturers of commercially available SARS-CoV-2 antigen tests commonly claim sensitivities over 90%. However, these values reflect results of studies done on individuals who meet the criteria for the intended use of the kits, i.e. diagnostics of COVID-19 in patients with clinical symptoms, not in a mixed population of symptomatic, asymptomatic and healthy persons.

In our study, we aimed to evaluate the performance of two antigen tests in a scenario close to the population-wide testing. In this regard, we tested a group of nearly 600 people who had no common epidemiological link between each other and visited the collection site to confirm or to rule out the infection.

METHODS

Subjects

Within a 4-day period in October 2020, we tested 591 individuals of 10 years of age or older, who attended a single collection site, dedicated to the SARS-CoV-2 specimen collection at the Motol University Hospital, Prague, Czech Republic, and consented to the study. The main reasons for their SARS-CoV-2 collection site

visit were either the suspicion of COVID-19 infection (273 patients) or contact tracing (290 cases). While 511 persons were referred by general practitioner or public health officer, 54 individuals were self-payers. The mean age of the cohort was 40 years (age range 12 to 78 years), 44.7% were males. Nearly one half of the population (290 subjects) self-reported presence of one or more of the following symptoms: cough, pain of muscles and/or joints, chills, diarrhoea and/or vomiting, elevated body temperature, loss of smell and/or taste. The study was approved by the hospital Ethics Committee (ref no EK-1286/20).

Antigen tests and PCR

Upon the subject's consent, we sampled three separate nasopharyngeal swabs and one additional swab from the oropharynx. Two nasopharyngeal samples were used onsite for two antigen detection assays according to the manufacturers' instructions: Panbio COVID-19 Ag Rapid Test (Abbott, Germany; hereafter referred to as "Ag test 1") and Standard F COVID-19 Ag FIA (SD Biosensor, Republic of Korea; hereafter referred to as "Ag test 2"). Briefly, the swab was first inserted into an extraction buffer provided with the kit, then the amount of 5 (Ag test 1) or 4 drops (Ag test 2) was loaded on the test device. The results were read after 15 minutes incubation at room temperature by a naked eye (Ag test 1) or after 30 minutes incubation at room temperature on the bench (Ag test 2) in the Standard F200 Analyser ('read-only' mode). In order not to unnecessarily lose the sensitivity of the assays, we ran antigen tests immediately upon collecting the sample and without the optional step of inserting the swab into the viral transport medium that may lead in undesirable antigen dilution.

The remaining nasopharyngeal swab along with the oropharyngeal swab were sampled in accordance with the international specimen collection guidelines (CDC, [9]). They were both inserted into the viral transport medium [10] and transported to the hospital microbiology laboratory for the PCR analysis. RNA extraction was performed with Viral Nucleic Acid Extraction kit (Zybio, China) on the EXM3000 instrument (Zybio, China). The extracts were subjected to the reverse transcription PCR, targeting N, E and RdRP/S genes (Allplex SARS-nCoV-2; Seegene, Republic of Korea), run on the CFX96 PCR cycler (Bio-Rad, USA). The sample was deemed positive if at least one of the genes was detected with a threshold cycle (Ct) value < 40; to define a single Ct for a respective sample, we used the lowest Ct out of the three detected targets.

RESULTS

The PCR positivity was detected in 223 cases (37.7%). Out of them, 168 people had one or more COVID-19

related symptoms (57.9% of all individuals with symptoms and 75.3% of all PCR positive cases), while 55 PCR positive subjects reported no symptoms at the time of sampling (48 of them were traced contacts). Ag test 1 and Ag test 2 were found positive in 148 and 141 cases, respectively (Table 1).

Test sensitivity increased to 0.738 (95% CI 0.667, 0.799) for the Ag test 1 and to 0.685 (95% CI 0.611, 0.750) for the Ag test 2 if only a subgroup of symptomatic patients (290 subjects) was analysed (data not shown). On the contrary, a low sensitivity value of 0.436 (95% CI 0.314, 0.567) for either of the Ag tests was found in asymptomatic persons (301 subjects).

The likelihood of detecting the SARS-CoV-2 antigen in a PCR positive person increased with decreasing PCR threshold cycle (Ct) (Table 2). The majority of PCR positive findings (161 of 223, i.e., 72%) had low Ct cycles < 30. In the vast majority of cases, these PCR results belonged to patients with COVID-19 associated symptoms (130 of 161 patients). Nevertheless, PCR results with Ct > 30 also comprised mostly the symptomatic patients (38 of 62 cases). Sensitivity of Ag tests was found greater than 80% only for samples with Ct < 30; a substantial drop in sensitivity to mere 12.9% was observed for samples with Ct > 30.

DISCUSSION

With the surge of the SARS-CoV-2 epidemic wave in autumn 2020, novel testing strategies to tackle the community transmission are being sought, including the option of population-wide screening with the aid of

antigen tests [4]. In our study, we mimicked a situation of mass screening in that we tested each individual, attending the hospital COVID-19 collection site, regardless of the presence or absence of clinical symptoms. Within 4 days, we enrolled nearly 600 individuals out of 800 eligible people who were 10 years or older. Our PCR positivity rate was almost 38% which was well in accordance with over 30% observed on a national level at the time of the study performance (daily reports on [11]).

We used two different antigen tests out of which one enabled europium fluorescence-based detection (Ag test 2), the technology believed to improve sensitivity. However, this mode of result visualisation did not have any impact on the change of sensitivity. Overall mean sensitivity values were 66.7% for Ag test 1 and 62.6% for Ag test 2. If the parameter of the presence of clinical symptoms is a criterion for performing the test, sensitivity increased only modestly to 73.8% for Ag test 1 and 68.5% for Ag test 2, while it dropped below 50% if asymptomatic, but PCR positive persons are tested.

Our findings fit well with the known sensitivity characteristics of antigen tests for other respiratory viruses like influenza or respiratory syncytial virus where rapid immunochromatography tests reach the sensitivity of 54.4% and 80%, respectively [12, 13]. Discrepancies between sensitivity values reported in research articles and manufacturers' leaflets come from differences in selection of tested samples. For instance, a clinical evaluation of the Ag test 2 with the claimed sensitivity of 100% was performed on a positive spiked material, not on real subjects. Interim data on Ag test 1 showed

Table 1. Number of positive and negative results when Ag test 1 (Table 1a) and Ag test 2 (Table 1b) are compared to PCR results (a)

		PCR		
		positive	negative	total
Ag test 1	positive	148	0	148
	negative	75	368	443
	Total	223	368	591
Result		Sensitivity 0.664 (95% CI 0.599,0.722)	Specificity 1.000 (95% CI 0.990, 1.000)	

(b)

		PCR		
		positive	negative	total
Ag test 2	positive	139	2	141
	negative	84	366	450
	Total	223	368	591
Result		Sensitivity 0.623 (95% CI 0.558, 0.684)	Specificity 0.995 (95% CI 0.980, 0.999)	

Abbreviations: Ag – antigen, CI – confidence interval, PCR – polymerase chain reaction

Table 2. Sensitivity of Ag test 1 and Ag test 2 in relation to the Ct if samples with higher Ct are added to the samples with lower Ct (Table 2a), and if samples with lower Ct are taken away from the samples with higher Ct (Table 2b)

(a)

PCR Ct	No pts	No symptomatic pts	No asymptomatic pts	Ag test 1 sensitivity (95% CI)	Ag test 2 sensitivity (95% CI)
< 20	51	43	8	0.922 (0.815,0.969)	0.922 (0.815,0.969)
< 25	121	99	22	0.926 (0.865,0.960)	0.901 (0.835,0.942)
< 30	161	130	31	0.870 (0.809,0.913)	0.814 (0.747,0.866)
< 35	190	154	36	0.779 (0.715,0.832)	0.726 (0.659,0.785)
≤ 40	223	168	55	see Table 1a	see Table 1b

(b)

PCR Ct	No pts	No symptomatic pts	No asymptomatic pts	Ag test 1 sensitivity (95% CI)	Ag test 2 sensitivity (95% CI)
> 20	172	125	47	0.587 (0.512,0.658)	0.535 (0.460,0.608)
> 25	102	69	33	0.353 (0.267,0.450)	0.294 (0.214,0.389)
> 30	62	38	24	0.129 (0.067,0.234)	0.129 (0.067,0.234)
> 35	33	14	19	0.0 (0.0,0.104)	0.03 (0.005,0.153)

Abbreviations: Ag – antigen; CI – confidence interval; Ct – cycle threshold; No pts – number of patients; PCR – polymerase chain reaction

the sensitivity of 85.5% (95% CI 78.2, 90.6), based on testing of 535 patients with suspicion of COVID-19 [14]. Of them, 77% were checked by the antigen test within three days from the onset of the symptoms, and 75% of them had their Ct < 25.

Similarly to Scohy et al. [8] we found out that the main attribute affecting the antigen test sensitivity is a viral load as estimated by the Ct. Lower viral load, represented in our study by high Ct values above 30, became hardly detectable by any of the two antigen tests used. Thus, patients with samples of late Ct values would be largely left undiagnosed, although many of them also presented with clinical symptoms in our study (38 of 62 patients). Regardless of their clinical state, it is important to point out that they all might be or soon become infectious as documented in studies on asymptomatic and presymptomatic persons [15, 16].

Because of the recent findings on infectivity [17], we can speculate that patients with low Ct were actually at the end of their infection stage and no longer posed the risk to others. However, our patient records show that only 5 of 62 patients with Ct > 30 visited the collection site to monitor the course of their infection (3 of them had still clinical symptoms), others were tested to diagnose the disease.

In reference to the aim of our study, i.e. to check the effectiveness of the mass testing with antigen tests, one limitation of the study is the bias in selection of the subjects. While most of them were indicated for the examination due to symptoms or contact tracing, the population-wide screening would include much higher number of healthy and asymptomatic people with low viral loads. This in turn would lead in even higher false negativity rate and a considerable risk of false positivity [18].

To conclude, in our opinion, the risk and rate of false negativity of antigen tests may have a significant negative impact on the effectiveness of outbreaks containment as it is crucial to identify any positive person on time, including the ones with initially low viral load. Not to miss them, a single round of testing, which is likely the case when a population-wide screening is ordered, seems insufficient and inadequate. Instead, the strategy based on repeated testing with high enough frequency [20] needs to be implemented if the antigen test is used as a frontline screening tool. In hospital settings and care homes, where false negativity can have an enormous negative impact on the care of misdiagnosed individuals and outbreak containment, antigen negative test should be followed by performing the more sensitive PCR.

REFERENCES

1. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA*, 2020;323:2249–2251.
2. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity – A Strategy for Containment. *N Engl J Med.*, 2020;383:e120.
3. WHO. Antigen detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays 2020. Available from: <https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2-infection-using-rapid-immunoassays>.
4. ECDC. Population-wide testing of SARS-CoV-2: country experiences and potential approaches in the EU/EEA and the United Kingdom 2020. Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-population-wide-testing-country-experiences.pdf>.
5. Azar MM, Landry ML. Detection of Influenza A and B Viruses and Respiratory Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests. *J Clin Microbiol.*, 2018;56:e00367–18.
6. Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque-Afonso AM, et al. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. *J Clin Microbiol.*, 2020;58:e00977–20.
7. Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, et al. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *J Clin Virol.*, 2020;129:104500.
8. Scohy A, Anantharajah A, Bodeus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. *J Clin Virol.*, 2020;129:104455.
9. CDC. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19 2020. Available from: <https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html>.
10. Kim C, Ahmed JA, Eid RB, Nyoka R, Waiboci LW, Erdman D, et al. Comparison of nasopharyngeal and oropharyngeal swabs for the diagnosis of eight respiratory viruses by real-time reverse transcription-PCR assays. *PLoS One*, 2011;6:e21610.
11. Ministry of Health CR. COVID-19: The summary of current situation in Czech Republic. Available from: <https://onemocneni-aktualne.mzcr.cz/covid-19>.
12. Merckx J, Wali R, Schiller I, Caya C, Gore GC, Chartrand C, et al. Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction: A Systematic Review and Meta-analysis. *Ann Intern Med.*, 2017;167:394–409.
13. Chartrand C, Tremblay N, Renaud C, Papenburg J. Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-analysis. *J Clin Microbiol.*, 2015;53:3738–3749.
14. FIND. FIND Evaluation of Abbott Panbio COVID-19 Ag Rapid Test Device External Report 2020. Available from: https://finddx.org/wp-content/uploads/2020/11/Panbio_Ag-Public-Report_v1_1.pdf.
15. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility – King County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep.*, 2020;69:377–381.
16. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med.*, 2020;382:2081–2090.
17. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation? *Clin Infect Dis.*, 2020. In press.
18. Sudlow C, Diggle P, Warlow O, Seymour D, Gordon B, Walker R, et al. Testing for coronavirus (SARS-CoV-2) infection in populations with low infection prevalence: the largely ignored problem of false positives and the value of repeat testing. *medRxiv.*, 2020.

Transparency declaration

Supported by the Ministry of Health of the Czech Republic – conceptual development of research organization Motol University Hospital, FNM. All authors report no conflicts of interest relevant to this article.

Acknowledgements

The authors are grateful to I. Adam, M. Sadilkova, K. Smolkova, M. Kalanday, I. Prosova, S. Strba, D. Kovarikova, B. Dzerengova, A. Hutnan, A. Shaker, V. Casarova and other staff members of Motol collection site for excellent technical assistance.

Do redakce došlo dne 10. 2. 2021.

Adresa pro korespondenci:

prof. MUDr. Pavel Dřevínek, Ph.D.

Ústav lékařské mikrobiologie 2. LF UK a FN Motol

V Úvalu 84

150 06 Praha

e-mail: pavel.drevinek@lfmotol.cuni.cz